NeoPhore
small molecule neoantigen immuno-oncology company
NeoPhore has raised €10M across 2 funding rounds from 6 investors, most recently a Series B round in Jan 2023. Based in Cambridge, UK; active in Healthtech. Data as of 28 Oct 2026.
Cambridge, UKwww.neophore.com ↗
Total raised
€10M
€10,182,234
Funding rounds
2
Investors
6
distinct backers
Active since
2017-11
latest 2023-01
Funding by year
EUR raised per yearNeoPhore — funding by year — interactive chart.
Data table
| NeoPhore — funding by year | |
|---|---|
| 2017 | €3.3M |
| 2023 | €6.8M |
Signals
High confidenceRaise-next likelihood10
base rate 48% for Series B
- ▼ Past typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood8
base rate 11% (2+ rounds)
- ▲ 9y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-01-19 | Series B | €6.8M | 2Invest,3B Future Health Fund,Astellas Venture Management,Claris Ventures,CRT Pioneer Fund | View deal → |
| 2017-11-16 | Other | €3.3M | Sixth Element Capital LLP (6EC) | View deal → |